FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

MOORE JANET
2. Issuer Name and Ticker or Trading Symbol

BIOMERICA INC [ BMRA ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

17571 VON KARMAN AVE.
3. Date of Earliest Transaction (MM/DD/YYYY)

10/28/2019
(Street)

IRVINE, CA 92614
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/28/2019  10/28/2019  G    3000  D  (1) 121720  D   
Common Stock                 635977  I  Trust 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Stock was a gift - no monetary transaction.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
MOORE JANET
17571 VON KARMAN AVE.
IRVINE, CA 92614
X
Chief Financial Officer

Signatures
/s/ Janet Moore 10/30/2019
**Signature of Reporting Person Date


Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Biomerica Charts.
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Biomerica Charts.

Biomerica Inc News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement
Monday 29 April 2024 (3 days ago) • GlobeNewswire Inc.
Biomerica provides update on inFoods® IBS expansion
Monday 15 April 2024 (2 weeks ago) • GlobeNewswire Inc.
Biomerica Reports Third Quarter 2024 Financial Results
Friday 12 April 2024 (3 weeks ago) • GlobeNewswire Inc.
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
Thursday 28 March 2024 (1 month ago) • GlobeNewswire Inc.
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board
Wednesday 21 February 2024 (2 months ago) • GlobeNewswire Inc.
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)
Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Friday 9 February 2024 (3 months ago) • Edgar (US Regulatory)
Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica
Tuesday 23 January 2024 (3 months ago) • GlobeNewswire Inc.
Biomerica Reports Second Quarter 2024 Financial Results
Tuesday 16 January 2024 (3 months ago) • GlobeNewswire Inc.
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 16 January 2024 (4 months ago) • Edgar (US Regulatory)
Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population
Monday 18 December 2023 (4 months ago) • GlobeNewswire Inc.
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 14 December 2023 (5 months ago) • Edgar (US Regulatory)